Related references
Note: Only part of the references are listed.Low-grade serous ovarian cancer: State of the science
Brian Slomovitz et al.
GYNECOLOGIC ONCOLOGY (2020)
Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D
Xin Yang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Visualizing and interpreting cancer genomics data via the Xena platform
Mary J. Goldman et al.
NATURE BIOTECHNOLOGY (2020)
SATB2 Versus CDX2 A Battle Royale for Diagnostic Supremacy in Mutinous Tumors
Stefan M. Brettfeld et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Epithelial ovarian cancer
Stephanie Lheureux et al.
LANCET (2019)
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Stephanie Lheureux et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer
Caroline Kreuzinger et al.
CANCER LETTERS (2019)
Ovarian cancer relapse: From the latest scientific evidence to the best practice
Daniela Luvero et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Current Status of Patient-Derived Ovarian Cancer Models
Yoshiaki Maru et al.
CELLS (2019)
Molecular profiling and molecular classification of endometrioid ovarian carcinomas
Paulina Cybulska et al.
GYNECOLOGIC ONCOLOGY (2019)
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach
Marica Garziera et al.
CELLS (2019)
Hopes and failures in front-line ovarian cancer therapy
Irina Tsibulak et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations
Rajmohan Murali et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)
Ovarian Cancer: A Heterogeneous Disease
Myriam Kossai et al.
PATHOBIOLOGY (2018)
ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies
Joseph J. Caumanns et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Recent Insights into Mucinous Ovarian Carcinoma
Francesca Ricci et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis
Luis Felipe Sallum et al.
Oncotarget (2018)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Christopher J. Ricketts et al.
CELL REPORTS (2018)
Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
Matilda X. Lee et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2018)
The secret lives of cancer cell lines
Robert E. Hynds et al.
DISEASE MODELS & MECHANISMS (2018)
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
S. Y. Cindy Yang et al.
GENOME MEDICINE (2018)
Frontline therapy of ovarian cancer: trials and tribulations
Jasmin Volpe et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2018)
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Peter F. Rambau et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2018)
Tumor evolution and chemoresistance in ovarian cancer
Soochi Kim et al.
NPJ PRECISION ONCOLOGY (2018)
Advances in ovarian cancer therapy
Alexander J. Cortez et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas
Kelsie L. Thu et al.
ONCOTARGET (2017)
TP53 Mutations in Breast and Ovarian Cancer
Laxmi Silwal-Pandit et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives
Tatjana Lazarevic et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients
Xiaohua Wu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Census and evaluation of p53 target genes
M. Fischer
ONCOGENE (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
Mutational heterogeneity in non-serous ovarian cancers
Jamie K. Teer et al.
SCIENTIFIC REPORTS (2017)
Variant Review with the Integrative Genomics Viewer
James T. Robinson et al.
CANCER RESEARCH (2017)
Front-line therapy of advanced epithelial ovarian cancer: standard treatment
C. Marth et al.
ANNALS OF ONCOLOGY (2017)
Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks
Ryusuke Murakami et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Dual Immunostain With SATB2 and CK20 Differentiates Appendiceal Mucinous Neoplasms From Ovarian Mucinous Neoplasms
Zaibo Li et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2017)
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
Andrew Goodspeed et al.
MOLECULAR CANCER RESEARCH (2016)
The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications
Ivo Meinhold-Heerlein et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2016)
The rise of genomic profiling in ovarian cancer
Rebecca A. Previs et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)
Wilms tumor protein 1 (WT1) - Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma
Eliane Tabea Taube et al.
GYNECOLOGIC ONCOLOGY (2016)
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
Liacine Bouaoun et al.
HUMAN MUTATION (2016)
dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs
Xiaoming Liu et al.
HUMAN MUTATION (2016)
An Immunohistochemical Algorithm for Ovarian Carcinoma Typing
Martin Kobel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2016)
Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining
Sarah Strickland et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update
Enis Afgan et al.
NUCLEIC ACIDS RESEARCH (2016)
Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies
Lorenza Mittempergher
CURRENT ONCOLOGY REPORTS (2016)
Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer
Angel Chao et al.
ONCOTARGET (2016)
TP53 mutations in epithelial ovarian cancer
Yu Zhang et al.
TRANSLATIONAL CANCER RESEARCH (2016)
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist et al.
JAMA ONCOLOGY (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours
Tan A. Ince et al.
NATURE COMMUNICATIONS (2015)
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors
Georgina L. Ryland et al.
GENOME MEDICINE (2015)
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Jaime Prat
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2014)
How Taxol/paclitaxel kills cancer cells
Beth A. Weaver
MOLECULAR BIOLOGY OF THE CELL (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Corine M. Beaufort et al.
PLOS ONE (2014)
Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma
Gian Franco Zannoni et al.
VIRCHOWS ARCHIV (2014)
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Daniela Luvero et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well- defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent
Marc Tischkowitz et al.
BMC MEDICAL GENETICS (2013)
ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas
Eleftherios P. Samartzis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
Weiva Sieh et al.
LANCET ONCOLOGY (2013)
Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Michael S. Anglesio et al.
PLoS One (2013)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke et al.
NATURE COMMUNICATIONS (2013)
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer
Isabelle J. Letourneau et al.
BMC CANCER (2012)
Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo
Ming Kei Lee et al.
CANCER CELL (2012)
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Zhigang C. Wang et al.
CLINICAL CANCER RESEARCH (2012)
A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3
Pablo Cingolani et al.
FLY (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Endometrial Carcinomas: A Review Emphasizing Overlapping and Distinctive Morphological and Immunohistochemical Features
Carla Bartosch et al.
ADVANCES IN ANATOMIC PATHOLOGY (2011)
Morphologic Spectrum of Immunohistochemically Characterized Clear Cell Carcinoma of the Ovary: A Study of 155 Cases
Deborah DeLair et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma
Linda E. Kelemen et al.
LANCET ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuan-Ting Kuo et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Ovarian clear cell carcinoma with papillary features: A potential mimic of serous tumor of low malignant potential
Ankur R. Sangoi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Characterization of three new serous epithelial ovarian cancer cell lines
Veronique Ouellet et al.
BMC CANCER (2008)
Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC)
Magdalena Zietarska et al.
MOLECULAR CARCINOGENESIS (2007)
Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer
Marie-Line Puiffe et al.
NEOPLASIA (2007)
Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer
Alberto Serrano-Olvera et al.
CANCER TREATMENT REVIEWS (2006)
Clonogenic assay of cells in vitro
Nicolaas A. P. Franken et al.
NATURE PROTOCOLS (2006)
Treatment issues in clear cell carcinoma of the ovary: A different entity?
Dimitrios Pectasides et al.
ONCOLOGIST (2006)
Expression of CD10 and cytokeratins in ovarian and renal clear cell carcinoma
Y Ohta et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2005)
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma:: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study
AJ González-Martín et al.
ANNALS OF ONCOLOGY (2005)
Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment
V Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma
RI Cameron et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2003)
p53 mutation is infrequent in clear cell carcinoma of the ovary
ESC Ho et al.
GYNECOLOGIC ONCOLOGY (2001)
Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma
CT Albarracin et al.
HUMAN PATHOLOGY (2000)
Share Paper
